Literature DB >> 18069756

Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis.

Oge Tascilar1, Güldeniz Karadeniz Cakmak, Ishak Ozel Tekin, Ali Ugur Emre, Bulent Hamdi Ucan, Burak Bahadir, Serefden Acikgoz, Oktay Irkorucu, Kemal Karakaya, Hakan Balbaloglu, Gurkan Kertis, Handan Ankarali, Mustafa Comert.   

Abstract

AIM: To investigate the effect of exogenous erythro-poietin (EPO) administration on acute lung injury (ALI) in an experimental model of sodium taurodeoxycholate- induced acute necrotizing pancreatitis (ANP).
METHODS: Forty-seven male Wistar albino rats were randomly divided into 7 groups: sham group (n = 5), 3 ANP groups (n = 7 each) and 3 EPO groups (n = 7 each). ANP was induced by retrograde infusion of 5% sodium taurodeoxycholate into the common bile duct. Rats in EPO groups received 1000 U/kg intramuscular EPO immediately after induction of ANP. Rats in ANP groups were given 1 mL normal saline instead. All animals were sacrificed at postoperative 24 h, 48 h and 72 h. Serum amilase, IL-2, IL-6 and lung tissue malondialdehyde (MDA) were measured. Pleural effusion volume and lung/body weight (LW/BW) ratios were calculated. Tissue levels of TNF-alpha, IL-2 and IL-6 were screened immunohistochemically. Additionally, ox-LDL accumulation was assessed with immune-fluorescent staining. Histopathological alterations in the lungs were also scored.
RESULTS: The mean pleural effusion volume, calculated LW/BW ratio, serum IL-6 and lung tissue MDA levels were significantly lower in EPO groups than in ANP groups. No statistically significant difference was observed in either serum or tissue values of IL-2 among the groups. The level of tumor necrosis factor-alpha (TNF-alpha) and IL-6 and accumulation of ox-LDL were evident in the lung tissues of ANP groups when compared to EPO groups, particularly at 72 h. Histopathological evaluation confirmed the improvement in lung injury parameters after exogenous EPO administration, particularly at 48 h and 72 h.
CONCLUSION: EPO administration leads to a significant decrease in ALI parameters by inhibiting polymorphonuclear leukocyte (PMNL) accumulation, decreasing the levels of proinflammatory cytokines in circulation, preserving microvascular endothelial cell integrity and reducing oxidative stress-associated lipid peroxidation and therefore, can be regarded as a cytoprotective agent in ANP-induced ALI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18069756      PMCID: PMC4171226          DOI: 10.3748/wjg.v13.i46.6172

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  43 in total

Review 1.  Cytokine storm in acute pancreatitis.

Authors:  Rohit Makhija; Andrew N Kingsnorth
Journal:  J Hepatobiliary Pancreat Surg       Date:  2002

2.  Acute lung injury in two experimental models of acute pancreatitis: infusion of saline or sodium taurocholate into the pancreatic duct.

Authors:  A Lichtenstein; R Milani; S M Fernezlian; A S Leme; V L Capelozzi; M A Martins
Journal:  Crit Care Med       Date:  2000-05       Impact factor: 7.598

3.  A paradigm shift for erythropoietin: no longer a specialized growth factor, but rather an all-purpose tissue-protective agent.

Authors:  R Savino; G Ciliberto
Journal:  Cell Death Differ       Date:  2004-07       Impact factor: 15.828

Review 4.  Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury.

Authors:  Z Z Chong; F Li; K Maiese
Journal:  Histol Histopathol       Date:  2005-01       Impact factor: 2.303

5.  Acute lung injury in experimental pancreatitis in rats: pulmonary protective effects of crotapotin and N-acetylcysteine.

Authors:  Adriana S Leme; Arnaldo Lichtenstein; Fernanda M Arantes-Costa; Elen C T Landucci; Milton A Martins
Journal:  Shock       Date:  2002-11       Impact factor: 3.454

6.  Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.

Authors:  Donna M Mancini; Stuart D Katz; Chim C Lang; John LaManca; Alhakam Hudaihed; Ana-Silvia Androne
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

7.  Respiratory mechanics and lung morphometry in severe pancreatitis-associated acute lung injury in rats.

Authors:  R Milani Júnior; P M Pereira; M Dolhnikoff; P H Saldiva; M A Martins
Journal:  Crit Care Med       Date:  1995-11       Impact factor: 7.598

8.  Effects of gabexate mesilate on serum inflammatory cytokines in rats with acute necrotizing pancreatitis.

Authors:  Chun-Chia Chen; Sun-Sang Wang; Shyh-Haw Tsay; Fa-Yauh Lee; Rei-Hwa Lu; Full-Young Chang; Shou-Dong Lee
Journal:  Cytokine       Date:  2006-02-10       Impact factor: 3.861

9.  Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats.

Authors:  Abdullah Kumral; Nazan Uysal; Kazim Tugyan; Atac Sonmez; Osman Yilmaz; Necati Gokmen; Muge Kiray; Sermin Genc; Nuray Duman; Tolga F Koroglu; Hasan Ozkan; Kursad Genc
Journal:  Behav Brain Res       Date:  2004-08-12       Impact factor: 3.332

Review 10.  Chemokines in acute respiratory distress syndrome.

Authors:  Padmam Puneet; Shabbir Moochhala; Madhav Bhatia
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-01       Impact factor: 5.464

View more
  23 in total

1.  Diabetes increases pancreatitis induced systemic inflammation but has little effect on inflammation and cell death in the lung.

Authors:  Dietmar Zechner; Marie Spitzner; Tassilo Müller-Graff; Brigitte Vollmar
Journal:  Int J Exp Pathol       Date:  2014-11-17       Impact factor: 1.925

2.  A nonerythropoietic peptide that mimics the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock.

Authors:  Nimesh S A Patel; Kiran K Nandra; Michael Brines; Massimo Collino; Ws Fred Wong; Amar Kapoor; Elisa Benetti; Fera Y Goh; Roberto Fantozzi; Anthony Cerami; Christoph Thiemermann
Journal:  Mol Med       Date:  2011-05-13       Impact factor: 6.354

3.  Erythropoietin Inhibits the Increase of Pulmonary Labile Zinc and the Expression of Inflammatory Mediators Following Subarachnoid Hemorrhage in Rats.

Authors:  Yiting Zhou; Xudong Zhao; Yanna Tang; Lin Zhu; Jianwei Jiang; Xiaojie Lu
Journal:  Neurocrit Care       Date:  2016-06       Impact factor: 3.210

4.  Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat.

Authors:  Joao Rocha; Maria Eduardo-Figueira; Andreia Barateiro; Adelaide Fernandes; Dora Brites; Rui Pinto; Marisa Freitas; Eduarda Fernandes; Helder Mota-Filipe; Bruno Sepodes
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 5.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

Review 6.  New strategies for Alzheimer's disease and cognitive impairment.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Oxid Med Cell Longev       Date:  2009 Nov-Dec       Impact factor: 6.543

Review 7.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

Review 8.  Oxidative stress: Biomarkers and novel therapeutic pathways.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Exp Gerontol       Date:  2010-01-11       Impact factor: 4.032

Review 9.  The vitamin nicotinamide: translating nutrition into clinical care.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Molecules       Date:  2009-09-09       Impact factor: 4.411

Review 10.  Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.

Authors:  Kenneth Maiese; Jinling Hou; Zhao Zhong Chong; Yan Chen Shang
Journal:  ScientificWorldJournal       Date:  2009-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.